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We read with great interest the paper by Collinson et al.1 recently
published in the European Journal of Clinical Nutrition.
The authors investigated the reasons for the high failure rate in
preventing hyperphosphataemia in haemodialysis patients (HD).
The intriguing conclusion of the study was that none of the
expected culprits—for example, drug insufficiency, limited dietary
information or advice, and dialysis dose or method—was actually
related with the problem. Hence, the suggestion to move to an
innovative education-based strategy. Two years ago, NephroCare
Medical Direction, a private organization accredited by the Italian
Public Health System that delivers dialysis treatment to >2000
patients in Italy, identified control of mineral bone disease (MBD)
as the topic of a clinical audit to be performed in all affiliated
centres. Two of the authors (ADC and PE) were asked to organize
the audit and take part in the procedure as external auditors after
an agreement with the public institution where they operate as
part of the full-time medical staff.
From July 2011 to September 2012 we recorded on an
individual anonymous chart: the demographic information, clinical
history, dialysis parameters (adequacy expressed as single-pool
KT/V—spKT/V), patient compliance, biochemical examinations and
data on pharmacological therapy.
Comorbidity was scored according to the Charlson comorbidity
index (CCI).2
The audit was conducted in accordance with the Declaration of
Helsinki, and all patients provided written informed consent
before data collection and analysis.
The clinical outcome indicators were taken from international
guidelines, but considering that the consensus on some MBD
therapeutic targets is not generalized3 we let each dialysis
centre choose between the 2003 Kidney Disease Outcomes
Quality Initiative (KDOQI) and the 2009 Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines4,5 and declare the choice
before the beginning of the audit. Compliance with prescribed
treatments was evaluated by administration of the Simplified
Medication Adherence Questionnaire (SMAQ) to each patient, a
tool that has been previously validated in haemodialysis patients,6
whereas compliance with dietary advice was evaluated after
administration of individual questionnaires by attending physicians.
A total of 170 patients from 18 centres were audited. Patient
characteristics are summarized in Table 1: 45 patients (30%) were
diabetic, whereas 16 (9.4%) had received previous kidney
transplantation and 7 (4%) had undergone parathyroidectomy.
In all, 153 (90%) patients underwent online haemodiafiltration
three times weekly; the mean spKT/V was 1.64 ± 0.37 and dialysate
calcium content was 1.5 mmol/l in 85.8% of the patients.
As shown in Table 1, the average phosphate and calcium
plasma levels were 1.38 ± 0.38 and 2.28 ± 0.21mmol/l, achieving
therapeutic targets (for phosphate: 1.13–1.78 mmol/l and for
calcium: 2.1–2.37mmol/l) in 59.4% and 68.2% of the cases,
respectively.
The mean intact parathyroid hormone (iPTH) levels were
32.8 ±35.1 pmol/l; the overall rate of patients achieving therapeutic
target was 38.2% and this percentage increased to 64% in centres
adopting the KDIGO guidelines (3/18 centres). In all, 28 patients
(16.4%) achieved the calcium, phosphate and iPTH targets
simultaneously.
Phosphate plasma levels were inversely correlated with age and
spKT/V (r2 0.07, Po0.001 and r2 0.05, Po0.005, respectively),
whereas they were directly related to iPTH levels (r2 0.05,
Po0.005).
Moreover, phosphate was significantly higher in patients
referring low adherence to diet compared with the more
compliant subjects (1.48 ± 0.38 vs 1.28 ± 0.32 pmol/l, Po0.005).
As shown in Table 2, there was a strong correlation between
compliance with medications and achievement of phosphate
therapeutic targets, although phosphate control was not
significantly associated with the P binders prescribed. Similarly,
achievement of PTH target was not related with any particular
drug prescribed to control hyperparathyroidism, and patients
taking calcimimetics were less likely to have calcium levels within
the recommended target.
Levels of MBD biochemical indicators were not related with the
presence of diabetes, CCI, compliance to diet or dialysis-related
factors.
Interestingly, not elderly patients (n= 62), when compared with
patients ⩾ 65 years (n= 108), presented significantly higher
phosphate and iPTH levels (1.48 ± 0.42 vs 1.27 ± 0.34 mmol/l,
Po0.05 and 38.8 ± 35.41 vs 29.58 ± 35.09 pmol/l, Po0.05,
respectively) and lower levels of CCI (3.5 ± 1.8 vs 4.3 ± 2.3,
Po0.05). Moreover, these patients presented a lower grade of
compliance with treatments (Fisher's exact test, P= 0.006) and a
reduced probability to achieve an adequate phosphate control
(Table 2).
Although MBD in HD patients is the object of primary clinical
and research interest, its prevention and treatment still remain
unsatisfactory, and the rate of failure in controlling the disease is
so high that it induces in care personnel some adaptive tolerance
as if it were an unavoidable condition.7 The results of the audit
reported here confirm the high failure rate in the achievement of
guideline targets, showing that only 16% of the evaluated patients
presented with calcium, phosphate and PTH levels simultaneously
controlled. Different reasons may account for the problem,
including some differences in guidelines that depend on weak
evidence and limited implementation.8
Current MBD management strategies imply the use of multiple
drugs, such as phosphate binders, vitamin D compounds and
calcimimetics, associated with an adequate dialysis prescription
and dietary restrictions. Our results clearly show that this drug-
centred approach is not sufficient to achieve therapeutic targets.
In fact, our audit highlights the strong relationship between the
achievement of therapeutic targets and the extent of compliance,
especially in younger patients, as also noticed by Collinson.
Accordingly, educational interventions involving dieticians,
dialysis nurses and patients have shown effectiveness in inducing
significant reductions in serum phosphate levels.9–11 We believe
that all the stakeholders involved in the care of MBD should be
aware of the scanty utility of pointing only to drug prescription
(using new drugs, changing timing or dose and so on) as the key
through which one can improve the control of MBD. By definition,
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in fact, any therapy cannot be effective if it is refused or missed by
the patient. Therefore, compliance has to be ranked as the first
aim of therapeutic intervention and deserves to be treated as the
objective of scientific research rather than a matter of good sense-
based counselling. A trained multidisciplinary staff including
physician, nurse, nutritionist, psychologist and professional
education expert should be dedicated to increase the compliance
in strict cooperation with family members. In addition, structured
programmes should be designed to improve the compliance and
their effectiveness should be tested in controlled prospective
studies.
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Table 1. Clinical characteristics and biochemical data of the HD
patients evaluated in the audit
N 170
Male/female 104/66
Age, years 67.8± 13.7
Dialytic age, months, median (IQR) 52.5 (25–93)
Diabetic patients, n (%) 45 (30)
CCI, median (IQR) 4 (2–5)
spKT/V 1.64± 0.37
Calcium serum levels (mmol/l) 2.28± 0.21
Pts on calcium target, n (%) 116 (68.2)
Phosphorus serum levels (mmol/l) 1.38± 0.38
Pts on phosphorus target, n (%) 101 (59.4)
iPTH serum levels (pmol/l) 32.8± 35.1
Pts on iPTH target, n (%)a 65 (38.2)
Medications
Phosphate binders, n (%) 105 (61.7)
Calcitriol (per os), n (%) 61 (35.8)
Paricalcitol, n (%) 37 (21.7)
Cinacalcet, n (%) 28 (16.4)
Compliance with medications, n (%)
Nonadherent 73 (42.9)
Adherent 97 (57.1)
Compliance with diet, n (%)
Nonadherent 82 (448.2)
Adherent 97 (51.8)
Abbreviations: CCI, Charlson comorbidity index; HD, haemodialysis
patients; iPTH, intact parathyroid hormone; IQR, interquartile range; os,
oral administration; pts, patients. Quantitative variables are expressed as
mean (± s.d.) or median and interquartile range; qualitative ones by
number and percentage. aPTH target was defined on the basis of
guidelines chosen and declared before the beginning of audit
(KDOQI:150–300 pg/ml or KDIGO: 2–9 upper limit of local laboratory).
Table 2. Analysis of the variables involved in the achievement of
therapeutic targets
Variables OR 95% CI P
Phosphorus on target
Compliance with drugs No 1.0 (Reference)
Yes 2.38 1.23–4.59 0.01
Use of phosphate binders No 1.0 (Reference)
Yes 1.63 0.86–3.1 0.14
Age o65 years No 1.0 (Reference)
Yes 0.48 0.25–0.92 0.03
PTH on target
Compliance with drugs No 1.0 (Reference)
Yes 0.93 0.49–1.76 0.8
Use of calcimimetics No 1.0 (Reference)
Yes 1.66 0.76–3.65 0.22
Use of paricalcitol No 1.0 (Reference)
Yes 0.48 0.19–1.03 0.08
Calcium on target
Compliance with drugs No 1.0 (Reference)
Yes 1.2 0.61–2.33 0.6
Use of calcimimetics No 1.0 (Reference)
Yes 0.34 0.15–0.76 0.01
Abbreviations: CI, confidence interval; OR, odds ratio; PTH, parathyroid
hormone. Odds ratio and confidence intervals were calculated by the two-
sided Fisher’s exact test. Po0.05 was considered statistically significant.
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